Home > News > Headline News > Archive

Click on title to read the full article.

FDA Grants IND to Investigator at University of Miami School of Medicine for Phase 2 Trial with AEZS-108 in Triple-Negative Brea

October 26, 2011

The U.S. Food and Drug Administration (FDA) has granted Alberto J. Montero, M.D., Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, an Investigational New Drug (IND) approval for the initiation of a randomized Phase 2 trial in chemotherapy refractory triple-negative (ER/PR/HER2-negative) luteinizing hormone-releasing hormone receptor (LHRH-R)-positive metastatic breast cancer with the Company's targeted cytotoxic LHRH analog, AEZS-108.

Research aims to understand the mechanisms of breast cancer

October 25, 2011

By Lee Campbell

CANCER RESEARCH WALES is trying to forge ahead in two of the most common battles in treating breast cancer – the spread of cancer to other parts of the body and resistance to traditional treatments.

ASCO Breast: DNA-Damaging Therapies Emerging as Possible Triple-Negative Breast Cancer Therapies

October 15, 2011

By Dave Levitan

Triple-negative breast cancers represent a challenge for patients and clinicians, with poorer prognosis and fewer treatment options than other breast cancer subtypes. Recently, though, there have been suggestions that targeting pathways that repair DNA within tumor cells could provide benefit beyond the currently available treatments.  

Professors get grants for metastatic breast cancer research

October 15, 2011

By Andrea Walker

An Annapolis group that raises money for research of metastatic breast cancer has awarded $75,000 in grants to two professors. METAvivor Research and Support said today it has awarded a $50,000 research grant to Alana Welm at the University of Utah and a $25,000 grant to Andrea Mastro at Penn State University.

Osteoporosis drug may extend survival in older, not younger, breast cancer patients

October 11, 2011

By EndocrineWeb.com

Though initially approved by the U.S. Food and Drug Administration (FDA) for use among osteoporosis patients, zoledronic acid may double as a life-extending therapy for older women with breast cancer.

However, younger women with breast carcinomas mighty actually experience harmful side effects from the drug, placing its net value as a supplementary breast cancer therapy at zero.

Blood Pressure Medication Works Against Breast Cancer

October 5, 2011

By Keely Walker, ABC Channel 7 News Denver

October is Breast Cancer Awareness month, researchers in Great Britain presented early results from a study confirming again that a blood pressure drug may help prevent metastatic breast cancer.

This study builds on work released earlier this year, and is giving new hope of finding ways to help more women conquer this cancer.

Regular Biopsies Needed in Relapsed Breast Cancer Patients

October 1, 2011

By Roxanne Nelson

Tumor hormone-receptor and HER2 status can change in breast cancer patients during the course of their disease. Because these changes can significantly influence survival and can completely change the patient's clinical management, these patients should undergo regular biopsies, according to a new study.

T-DM1 improved PFS in HER-2–positive, metastatic breast cancer

October 1, 2011

An antibody drug conjugate, trastuzumab emtansine, improved PFS in women with HER-2–positive metastatic breast cancer, according to results of a phase 2 trial presented at the 2011 European Multidisciplinary Cancer Congress.